TRAVERE THERAPEUTICS INC (TVTX)
Health Care · Biotechnology · NASDAQ
A biopharmaceutical company developing and commercializing innovative therapies to address rare kidney and metabolic diseases with high unmet need.
What TRAVERE THERAPEUTICS INC does
Travere Therapeutics is a biopharmaceutical company focused on identifying, developing, and delivering therapies for rare kidney and metabolic diseases. The company's portfolio includes approved products and a clinical-stage pipeline targeting significant unmet medical needs in conditions like Immunoglobulin A nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS).
Themes: rare diseases, kidney disease / nephrology, drug commercialization, orphan drugs
Fundamentals
- Price$65.71 as of 2026-08-21 close
- Market cap$6.2B as of 2026-08-21
- 1-year return+269.4% 2025-08-21 close $17.79 → 2026-08-21 close $65.71
- P/En/a negative earnings
- Net margin-7.3% as of 2026-08-24
- Gross margin+98.6% as of 2026-08-24
- ROE-55.8% as of 2026-08-24
- Debt / equity24.58 as of 2026-08-24
- Revenue growth (YoY)+77.1% as of 2026-08-24
- Revenue CAGR (3y)+64.9% SEC XBRL
- Beta1.11 as of 2026-08-24
- Last reported earnings2026-08-04 SEC EDGAR Form 8-K (Item 2.02)
How TVTX compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross margintop 10% 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRtop 10% 402 covered Health Care peers
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
TVTX is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no shareholder return data.
Short-term score
55.0 #483 of 1,704 scored · #94 of 240 in Health Care
Volume and participation 85th: it gapped 10.7% above the previous close and has not traded back through the level it left behind — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed; trend 84th: a strong uptrend, with buyers in control; weakest is setup 37th: over the past year its closes ranged, and it has retraced essentially none of its move over the past year — 1% of it. Its score is docked 10 points for overextended (RSI above 75 or stochastic above 90).
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How TRAVERE THERAPEUTICS INC looks technically
TRAVERE THERAPEUTICS INC (TVTX) is trading 61.9% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 228 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 32, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 67, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 3 trading days ago. It is 1.0% below its all-time high.
Trend
8
| Distance from the 200-day | it is trading 61.9% above its 200-day average, the long-term trend line — a longer-term uptrend | +61.9% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $57.90 | $57.90 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $40.59 | $40.59 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 16 calendar days ago — the swings before that are what the structure reading is measured on | 16 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that upward direction; the labelling fails if price closes below 60. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a completed three-part correction. | possible upward five-wave sequence, in wave 4 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 228 trading days ago — a "golden cross", a bullish long-term signal | 228 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 32, with buyers in control | 31.6 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 67, neither overbought (above 70) nor oversold (below 30) | 67.4 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($54.22 to $66.38) — its "stochastic" reading is 94 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 94.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 13 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $66.38 | $66.38 |
|---|---|---|
| From the 52-week high | it is 1.0% below its 52-week high (its highest price of the past year) | -1.0% |
| Above the 52-week low | it is 285.4% above its 52-week low (its lowest price of the past year) | +285.4% |
| Below the 52-week high | it is 1.0% below its highest point of the past year | 1.0% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $66.38 (set on 2026-08-21) | $66.38 |
| Given back of the 52-week move | over the past year its closes ranged ($17.23 to $65.96), and it has given back essentially none of its rise from last year’s low — 1% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $34.29 to $35.84. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.5% |
| From the all-time high | it is 1.0% below its all-time high | -1.0% |
| Nearest price level | it is trading 8.8% above a support level at $59.93 — a price it turned at three times since 2026-06-25, most recently on 2026-07-23. Since 2024-08-21 it has 14 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -8.8% |
| All-time low | its lowest closing price on record is $1.50 (set on 2012-11-08) | $1.50 |
| Above the all-time low | it is 4280.7% above its all-time low | +4,281% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 71% of it) | 71st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.56 between its high and its low — about 3.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.56 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $53.37 and $67.56 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $53.37 – $60.46 – $67.56 |
| Typical daily range (% of price) | its price moves about 3.9% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.9% |
| Stretch from the 200-day average | it is trading 9.8 daily ranges above its 200-day average price (61.9% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 9.8 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.07× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 1.5% since the prior reading | +1.5% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.5% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +0.5% |
|---|---|---|
| Open gap | it gapped 10.7% above the previous close 12 sessions ago and has not traded back through the level it left behind at 56.02 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +10.7% |
| Gap filled | a 2.6% gap down opened on 2026-07-23 has been "filled" 21 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 21 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 13.8 percentage points (the stock gained 16.1% while the market gained 2.3%) | +13.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 43.8 percentage points (the stock gained 46.9% while the market gained 3.1%) | +43.8% |
| vs market, 6 months | over the past 6 months this stock beat the market by 105.2 percentage points (the stock gained 116.2% while the market gained 11.1%) | +105.2% |
| vs market, 12 months | over the past 12 months this stock beat the market by 248.9 percentage points (the stock gained 269.4% while the market gained 20.5%) | +248.9% |
Signal agreement
2
| Bullish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 20% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 7.3% of the share price. | +20.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 56% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $42.05 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | +56.3% |
|---|---|---|
| Vs the average paid since it last reported | the price is 6% above the average price paid since it last reported on 2026-08-04 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $62.18 — a volume-weighted average of daily closes over 14 sessions, not a true tick-by-tick VWAP. | +5.7% |
Price levels it has turned at before
TVTX last closed at $65.71 on 2026-08-21. Since 2024-08-21 it has turned at 14 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $59.93 | Support | 8.8% below the last close | turned there three times · 2026-06-25 to 2026-07-23 |
| $53.21 | Support | 19.0% below the last close | turned there twice · 2026-07-17 to 2026-08-03 |
| $48.59 | Support | 26.1% below the last close | turned there twice · 2026-05-05 to 2026-05-29 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes below $60.00.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $60.00 and $63.21 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a completed three-part correction, which fails on a close above $66.24.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Near the 52-week high · Broke out to a new 20-day high · in a strong, established uptrend (ADX) · Analyst price target recently RAISED · Near the all-time high | Learn: moving average · golden cross · adx · rsi · breakout · all time high
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.27 mean, 1=Strong Buy…5=Strong Sell) — 14 analysts
- Mean price target$72.79 range $49.00 – $90.00; median $75.00
Analyst estimates, as of 2026-08-17. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for TVTX
- Consensus EPS estimate$0.5011 next reporting period, as of 2026-08-17
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on the successful commercialization of FILSPARI (sparsentan)","Risks associated with clinical trial outcomes and regulatory approval processes","Potential for future capital requirements to fund operations and R&D"]
What changed in the latest 10-Q
AI-assisted comparison of TVTX's 10-Q filed 2026-05-04 against the prior one filed 2025-10-30.
Management's Discussion & Analysis (MD&A)
- Added:
- Footnote 2 in newer filing (filed 2026-05-04): 'On April 13, 2026, the FDA granted full (traditional) approval of FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis ("FSGS") without nephrotic syndrome.'
- Footnote 3 in newer filing (filed 2026-05-04): 'Following a voluntarily pause in enrollment, we restarted enrollment activities for the pivotal Phase 3 HARMONY Study in the first quarter of 2026.'
- Section heading change in newer filing: 'FILSPARI® (sparsentan) for the treatment of IgAN' (more specific than older 'FILSPARI® (sparsentan)')
- Removed:
- Footnote 2 in older filing (filed 2025-10-30): 'In May 2025, we announced that the FDA accepted our sNDA for traditional approval of FILSPARI for the treatment of FSGS and assigned a PDUFA target action date of January 13, 2026.'
- Footnote 3 in older filing (filed 2025-10-30): 'In September 2024, we voluntarily paused enrollment in the Phase 3 HARMONY Study, as described below.'
- Text in older filing referencing 'DEARA' acronym: 'FILSPARI is a dual endothelin angiotensin receptor antagonist (DEARA).' - acronym removed in newer filing
- Reworded:
- Reference date change: 'audited financial statements and notes thereto as of and for the year ended December 31, 2024' (older, filed 2025-10-30) changed to 'year ended December 31, 2025' (newer, filed 2026-05-04)
- Reference date change: 'Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (SEC) on February 21, 2025' (older) changed to 'year ended December 31, 2025, filed with the Securities and Exchange Commission ("SEC") on February 19, 2026' (newer)
- Quotation mark style change: 'SEC' changed to '"SEC"' in newer filing
- Text in older filing: 'FILSPARI® (sparsentan)' section heading changed to more specific 'FILSPARI® (sparsentan) for the treatment of IgAN' in newer filing
- Abbreviation formatting: '(ACE) inhibitor or angiotensin receptor blockers (ARB)' in older changed to '("ACE") inhibitor or angiotensin receptor blockers ("ARB")' in newer filing
- Abbreviation formatting: 'REMS' changed to '"REMS"' in newer filing
- Page number changed from '27' in older filing to '25' in newer filing
- Notes:
- The two texts are substantially similar in content; most differences are metadata-related (fiscal year references, filing dates) or minor formatting changes.
- The ending of both text excerpts is truncated mid-sentence regarding European Commission authorization, so comparison at the document boundary may be incomplete.
Risk Factors
- Added:
- FILSPARI approval for FSGS: full (traditional) approval granted by FDA in April 2026
- Reference to FSGS indication: "reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome"
- Language about FILSPARI being "the first and only medicine approved by the FDA for the treatment of FSGS"
- Reference to FSGS commercialization challenges: "in particular as it relates to the launch and commercialization in FSGS"
- Updated language specifying commercialization plans for both IgAN and FSGS: "and in FSGS in April 2026"
- Reference to "full (traditional) approval label for FSGS" in physician/payer response discussion
- Removed:
- Reference to ASEAN member states in the territories list (older filing stated: "including Europe, Australia, New Zealand, Japan, South Korea, Taiwan, the ASEAN member states, Brazil, Chile, Israel and the Gulf Cooperation Council countries")
- Final sentence in older filing: "We are dependent on third parties for the successful commercialization of sparsentan in certain key ter" (text appears truncated in both, but this reference is removed or reordered in newer version)
- Reworded:
- Expanded description of IgAN indication to add: "which was granted full approval by the FDA in September 2024" (separating from accelerated approval history)
- Changed from "As a product for a rare disease that had no previously-approved non-immunosuppressive treatment, the successful launch and commercialization of FILSPARI is subject to many risks" to longer formulation discussing both IgAN and FSGS separately
- Changed scope from "FILSPARI for IgAN patients" to "FILSPARI for IgAN and FSGS patients" in commercial success discussion
- Updated reference from "if the addressable patient population suffering from primary IgAN" to include both "primary IgAN or FSGS"
- Changed sales force history language from "until the commencement of our commercial launch in February 2023, no one in our sales force had promoted FILSPARI or any other medicine for the treatment of IgAN patients" to "until the commencement of our commercial launch in IgAN in February 2023, and in FSGS in April 2026, no one in our sales force had promoted FILSPARI for the treatment of IgAN or FSGS patients, respectively"
- Reference to April 10-K changed from fiscal year 2024 filed February 21, 2025 to fiscal year 2025 filed February 19, 2026
- Notes:
- Both filings appear truncated at the end of the provided excerpts, limiting assessment of potential later changes
- The older filing text provided ends with "We are dependent on third parties for the successful commercialization of sparsentan in certain key ter" suggesting possible truncation
- Full scope of all Risk Factors changes cannot be assessed due to incomplete section text in both versions
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 7 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 5 sells ($632846) — 1 selling insider
- Last 90 days0 buys · 7 sells ($1M) — 3 selling insiders
- Last 180 days0 buys · 45 sells ($17M) — 11 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-18. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about TVTX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding TVTX as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 26,167,431
- Reported value $777,434,353
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
TVTX had 11,676,586 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
TVTX had 12.4% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 9.41 days to cover at the same settlement.
- Reported short interest (shares) 11,676,586
- Short interest (% of shares outstanding) 12.4%
- Prior settlement (shares) 12,015,392
- Reported change -2.82%
- Days to cover (reported) 9.41
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Calliditas Therapeutics (CALT)
- Chinook Therapeutics (acquired by Novartis)
- Vera Therapeutics (VERA)
- Omeros Corporation (OMER)
- Retrophin (predecessor entity)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare TVTX vs…
TRAVERE THERAPEUTICS INC is found in…
Frequently asked questions
What does TRAVERE THERAPEUTICS INC (TVTX) do?
Travere Therapeutics is a biopharmaceutical company focused on identifying, developing, and delivering therapies for rare kidney and metabolic diseases. The company's portfolio includes approved products and a clinical-stage pipeline targeting significant unmet medical needs in conditions like Immunoglobulin A nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS).
What sector is TRAVERE THERAPEUTICS INC (TVTX) in?
TRAVERE THERAPEUTICS INC (TVTX) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are TRAVERE THERAPEUTICS INC's (TVTX) competitors?
Notable peers of TRAVERE THERAPEUTICS INC (TVTX) include Calliditas Therapeutics, Chinook Therapeutics (acquired by Novartis), Vera Therapeutics, Omeros Corporation and Retrophin (predecessor entity). This peer set is informational only — not financial advice.
Is TRAVERE THERAPEUTICS INC (TVTX) overbought or oversold right now?
TRAVERE THERAPEUTICS INC (TVTX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 67, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on TVTX come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.